BOTHELL, Wash.--(BUSINESS WIRE)--Seattle Genetics, Inc. (Nasdaq:SGEN) today reported financial results for the third quarter and nine months ended September 30, 2011. The company also highlighted the ADCETRIS (brentuximab vedotin) product launch, recent product development activities and upcoming milestones.
